HEALTH

3M introduces Rapid Detection flu test

BY Michael Johnsen

ST. PAUL, Minn 3M on Thursday announced the nationwide availability of the 3M Rapid Detection Flu A+B Test, an innovation in the flu diagnostics market.

The 3M Rapid Detection Flu A+B Test is the first rapid flu test to provide automated results. The automated technology helps reduce user interpretation errors, which can lead to both false-negative or false-positive results. The 3M Rapid Detection Flu A+B Test will be able to deliver hospital and physician office laboratories reliable and objective electronic results in 15 minutes.

“Bringing automation to the interpretation of influenza tests is a key factor for the next generation of rapid flu tests,” said Brian Anderson, marketing manager of 3M Health Care. “Automating and storing the objective result of a flu test will help increase laboratory productivity and minimize the potential for human error, which can contribute to improving patient outcomes.”

Requiring less than three minutes of prep time, the 3M Rapid Detection Flu A+B Test detects positive or negative results and differentiates influenza A and influenza B. In addition to providing automated results, the technology also enables labs to export data through laboratory information systems, further reducing the potential for reporting error by eliminating the need for manual recording and transferring of patient results. The test also reads and stores lab results, giving lab technicians more flexibility in time and test management.

“Properly interpreting test results is critical, especially considering that most flu antiviral medications have a 48-hour recommended therapeutic window for prescribing, so false-positives or even delayed test results may result in misapplication of therapy or may reduce its effectiveness,” stated Christine Ginocchio, director of microbiology, virology and molecular diagnostics at North Shore Long Island Jewish Health System. “Having an automated reader almost eliminates the potential for misinterpreting results, leading to a faster and more informed treatment decision, which results in better patient outcomes.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

ASCP launches chronic constipation education initiative

BY Michael Johnsen

ALEXANDRIA, Va. The American Society of Consultant Pharmacists on Thursday launched a comprehensive continuing medical education initiative for physicians, nurses, pharmacists and other health-care providers about chronic constipation.

Known as E-IMPACCT, Elderly IMProvements and Advances in Chronic Constipation Treatment, the program presents educational activities on evaluating and managing CC, and offers a range of tools to help clinicians in everyday practice.

 “Because of the cascade of complex health issues that can be triggered by chronic constipation, clinicians have expressed their need for targeted education about CC,” stated ASCP executive director and chief executive officer John Feather. “Clinicians need to identify, recognize and differentiate CC and have a clear understanding of the pros and cons of each of the treatments and medications, the side effects and administration and efficacy data.”

“For all clinicians, the management strategies for treating chronic constipation in the elderly should include a combination of patient and caregiver education and communication, dietary modifications, and treatment options,” commented ASCP director of professional and educational affairs Trish D’Antonio Mazzuca. “Educational outcomes from E-IMPACCT will measure changes in clinician knowledge and behavior and improvements in patient care.”

E-IMPACCT provides outcomes-based knowledge through an ongoing, thorough awareness campaign with educational components that will roll out over a 12-month period. Through this initiative, participants are presented with new information and certified continuing education activities, patient cases and guidelines designed to help clinicians better manage CC and improve outcomes in today’s seniors.

Chronic constipation is the most common digestive complaint in the general population. In seniors, roughly 26 percent of men and 34 percent of women complain of constipation. Americans spend approximately $800 million per year on over-the-counter laxatives, the society reported.

The ASCP E-IMPACCT initiative is supported by an educational grant from Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

GlaxoSmithKline wins recommendation to sell Alli in Europe

BY Michael Johnsen

LONDON GlaxoSmithKline won a recommendation from European regulators Thursday that it be allowed to sell its weight loss drug Alli over-the-counter in Europe.

The European Medicines Agency said it had recommended the switch from prescription-only to nonprescription for a 60-milligram dose of alli, the same dose approved for sale OTC in the United States. The European Commission now needs to rubber-stamp the recommendation.

The European Medicines Agency said it had recommended the switch from prescription-only to nonprescription for a 60-milligram dose of alli, the same dose approved for sale OTC in the United States. The European Commission now needs to rubber-stamp the recommendation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?